ClinicalThought: Cancer Immunotherapy

Five ClinicalThought commentaries collated into an educational module provide expert discussion of how to optimally integrate cancer immunotherapies into patient care. Key factors affecting this therapeutic approach are addressed including recent clinical trial data on the efficacy and adverse events associated with newer immunotherapies.

Share

Program Content

Activities

Taking a BiTE Out of ALL
Taking a BiTE Out of ALL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2015

Expires: October 14, 2016

Immunotherapy-Related Adverse Events
How I Manage Immunotherapy-Related Adverse Events in My Patients Receiving Blinatumomab
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2015

Expires: November 15, 2016

T-VEC for Melanoma
Newly Approved: T-VEC for Melanoma After Resection
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 11, 2016

Expires: January 09, 2017

CAR T Cells
What You Need to Know About CAR T Cells
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2016

Expires: February 02, 2017

Immunotherapeutic Combos for Leukemia/Lymphoma
New Immunotherapeutic Combinations for Hematologic Malignancies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2016

Expires: February 24, 2017

Faculty

cover img faculity

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Howard L. Kaufman, MD

Associate Director for Clinical Sciences
Chief Surgical Officer

Department of Surgical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

cover img faculity

Jonathan Webster, MD

Fellow
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.